Who
James Brian Windsor
Director and Officer
Company insider
Files Form 4 as: President and CEO, Rein Therapeutics; Chief Science Officer, TFF Pharmaceuticals.
In numbers
- Trades disclosed
- 18
- Buys
- 5
- Sells
- 1
- Bought
- $87K
- Sold
- $395K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Oct 2019
- Last trade
- 8 May 2026
- Last filed
- 13 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 May 2026filed 13 May 2026 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 8 May 2026filed 13 May 2026 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 30 Apr 2026filed 13 May 2026 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K25,000 at $1.00 | filing |
| 30 Apr 2026filed 13 May 2026 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K25,000 at $1.00 | filing |
| 5 Dec 2024filed 9 Dec 2024 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $535239 at $2.24 | filing |
| 5 Dec 2024filed 9 Dec 2024 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $362161 at $2.25 | filing |
| 2 Dec 2024filed 4 Dec 2024 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —517,500 at $0.00 | filing |
| 5 Mar 2024filed 6 Mar 2024 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2 | filing |
| 5 Mar 2024filed 6 Mar 2024 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Code M | —2,000 | filing |
| 15 Dec 2023filed 18 Dec 2023 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $758225 at $3.37 | filing |
| 20 Nov 2023filed 21 Nov 2023 | RNTX Rein TherapeuticsBiotechnology | SEC FORM 4 Bought | $10,0005,076 at $1.97 | filing |
| 7 Dec 2020filed 9 Dec 2020 | TFF Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 7 Dec 2020filed 9 Dec 2020 | TFF Pharmaceuticals | SEC FORM 4 Code M | $63K25,000 at $2.50 | filing |
| 7 Dec 2020filed 9 Dec 2020 | TFF Pharmaceuticals | SEC FORM 4 Sold | $395K25,000 at $15.80 | filing |
| 24 Aug 2020filed 26 Aug 2020 | TFF Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 29 Nov 2019filed 3 Dec 2019 | TFF Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —3,623 at $0.00 | filing |
| 29 Oct 2019filed 29 Oct 2019 | TFF Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —43,794 at $0.00 | filing |
| 25 Oct 2019filed 29 Oct 2019 | TFF Pharmaceuticals | SEC FORM 4 Bought | $25K5,000 at $5.00 | filing |
News
No headline names them, or the companies they trade most, lately.